| Ytd | 189.14% | |
| 1y | 189.14% |
| Open | 109.67 | Prev Close | 110.75 | Low | 109.01 | High | 110.47 | Mkt Cap | 4.59B |
| Vol | 42.31K | Avg Vol | 684.31K | EPS | -3.14 | P/E | -34.96 | Forward P/E | -37.52 |
| Beta | N/A | Short Ratio | 4.97 | Inst. Own | 87.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 108.32 | 200-d Avg | 84.82 | 1yr Est | 163.50 |
MANE News
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company
Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in
Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition propo
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of
B. Riley Securities analyst Mayank Mamtani initiates coverage on Veradermics (NYSE:MANE) with a B
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq